Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
about
Biomarkers in preclinical cancer imaging.Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy.(18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.Effect of antisense microRNA targeting survivin on rectal cancer HRC-9698 cells and its mechanismComparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.
P2860
Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@en
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@nl
type
label
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@en
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@nl
prefLabel
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@en
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@nl
P2093
P2860
P1476
Clinical significance of VEGFR ...... ated with neoadjuvant therapy.
@en
P2093
Carlos Ferrer
Emilio Alvarez
Enrique Ochoa
Felipe A Calvo
Isabel Peligros
Jose L Carreras
Pilar Garcia-Alfonso
Rafael Herranz
P2860
P2888
P304
P356
10.1007/S00259-013-2479-7
P577
2013-06-26T00:00:00Z